TRAP-Targeting Nanoparticles for Tendon Regeneration

Resolve Bottlenecks,
Find Innovative SolutionsGenerate Solutions

Solution Overview

Problem

Current treatments for tendon injuries, such as tendinopathy or tendon rupture, lack effective methods for promoting tendon regeneration, particularly in specific anatomical locations and healing stages, leading to variable healing outcomes and ongoing disability.

Innovation Solution

A composition for controlled local delivery of therapeutic agents to injured tendons, utilizing a targeting ligand tethered to a polymer, specifically binding to tartrate-resistant acid phosphatase (TRAP), which includes peptides like TRAP Binding Peptide (TBP) and therapeutic agents like azeliragon, to enhance tendon regeneration.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Reliability

If conventional treatments are used for tendon injuries, then general wound healing occurs through inflammatory, proliferative, and remodeling phases, but healing outcomes are variable and tendon regeneration is insufficient

Engineering Contradiction:

Improvehealing outcome consistencyVSAvoidtendon regeneration efficiency

Core Design Contradiction:

ReliabilityVSProductivity

Solution Approach 1:

The patent applies preliminary action by administering therapeutic agents at specific early time points (day 1, 3, or 7 post-injury) to target the inflammatory and early proliferative phases of tendon healing. This timing strategy intervenes before the remodeling phase begins, establishing favorable conditions for regeneration before scar tissue formation occurs, thereby improving both consistency and efficiency of healing outcomes

Inventive Principle:

Principle #10Preliminary action

Solution Approach 2:

The patent implements local quality by delivering therapeutic agents directly to the injured tendon site through local injection rather than systemic administration. This localized delivery concentrates the therapeutic effect at the injury site during critical early phases, enhancing regeneration efficiency while maintaining consistent outcomes across different subjects

Inventive Principle:

Principle #3Local quality

2Quantity of substance

If therapeutic agents are delivered systemically, then broad coverage is achieved, but local concentration at the injury site is insufficient for effective tendon regeneration

Engineering Contradiction:

Improvetherapeutic agent distributionVSAvoidtendon regeneration efficiency

Core Design Contradiction:

Quantity of substanceVSProductivity

Solution Approach 1:

The patent resolves this contradiction by shifting from systemic to local delivery of therapeutic agents. Local injection ensures high concentration of the agent at the injury site during critical early phases, maximizing regeneration efficiency while using smaller total doses compared to systemic administration

Inventive Principle:

Principle #3Local quality

3Stability of the object's composition

If treatment is delayed until later healing stages, then inflammation has subsided, but the window for optimal tendon regeneration has passed and scar tissue formation has begun

Engineering Contradiction:

Improveinflammatory response controlVSAvoidregeneration window opportunity

Core Design Contradiction:

Stability of the object's compositionVSLoss of time

Solution Approach 1:

The patent applies preliminary action by targeting the therapeutic intervention to the inflammatory and early proliferative phases (days 1-7 post-injury) rather than waiting for inflammation to subside. This early timing captures the regeneration window before scar tissue formation dominates, preventing loss of the critical regeneration opportunity while still allowing natural inflammatory resolution to occur

Inventive Principle:

Principle #10Preliminary action

4Reliability

If multiple treatment sessions are administered, then therapeutic effect is enhanced, but treatment complexity and time commitment increase

Engineering Contradiction:

Improvetendon regeneration effectivenessVSAvoidtreatment protocol complexity

Core Design Contradiction:

ReliabilityVSDevice complexity

Solution Approach 1:

The patent reduces treatment complexity by concentrating therapeutic delivery into a limited number of early sessions (days 1, 3, or 7) during the critical inflammatory and proliferative phases. This approach achieves effective regeneration with fewer sessions compared to prolonged treatment protocols, as the early intervention establishes favorable conditions that reduce the need for continued treatment

Inventive Principle:

Principle #10Preliminary action

Applied Scientific Principles

This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.

Function Achieved in This Case

The targeted delivery of therapeutic agents to injured tendons during specific healing stages, like the late inflammatory and early proliferative phases, significantly enhances tendon regeneration, improving healing outcomes and reducing scar tissue formation.

Implementation Method 1

the targeting ligand specifically binds to a target associated with a site in need of tendon regeneration

Methodology Applied

Scientific EffectSpecific binding:

Data Source

PatentUS20230293704A1Compositions and Methods for Tendon Regeneration

Publication Date: 2023.09.21 UNIVERSITY OF ROCHESTER

AI summary

The present invention generally relates to novel compositions and methods for promoting regeneration of injured tendon. In some aspects, the composition comprises a nanoparticle that targets specifically to injured tendon to deliver a therapeutic agent that promotes tendon regeneration. In certain aspects, the methods comprise administering to a subject in need thereof a nanoparticle that targets specifically to injured tendon to deliver a therapeutic agent that promotes tendon regeneration.